Avaccine is a biological preparation that improves immunity to a particulardisease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe or its toxins. The agent stimulates the body'simmune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.[1]
^Enria, D. A.; Ambrosio, A. M.; Briggiler, A. M.; Feuillade, M. R.; Crivelli, E.; Study Group on Argentine Hemorrhagic Fever Vaccine (2010). "Candid#1 vaccine against Argentine hemorrhagic fever produced in Argentina. Immunogenicity and safety".Medicina.70 (3):215–222.PMID20529769.
^Kuschner, R. A.; Russell, K. L.; Abuja, M.; Bauer, K. M.; Faix, D. J.; Hait, H.; Henrick, J.; Jacobs, M.; Liss, A.; Lynch, J. A.; Liu, Q.; Lyons, A. G.; Malik, M.; Moon, J. E.; Stubbs, J.; Sun, W.; Tang, D.; Towle, A. C.; Walsh, D. S.; Wilkerson, D.; Adenovirus Vaccine Efficacy Trial Consortium (2013). "A phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of the live, oral adenovirus type 4 and type 7 vaccine, in U.S. Military recruits".Vaccine.31 (28):2963–2971.doi:10.1016/j.vaccine.2013.04.035.PMID23623865.
^Kim, D. S.; Nam, J. H. (2010). "Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines".Expert Opinion on Biological Therapy.10 (2):179–190.doi:10.1517/14712590903379502.PMID20088713.S2CID2700243.
^Zhu, F. C.; Liang, Z. L.; Li, X. L.; Ge, H. M.; Meng, F. Y.; Mao, Q. Y.; Zhang, Y. T.; Hu, Y. M.; Zhang, Z. Y.; Li, J. X.; Gao, F.; Chen, Q. H.; Zhu, Q. Y.; Chu, K.; Wu, X.; Yao, X.; Guo, H. J.; Chen, X. Q.; Liu, P.; Dong, Y. Y.; Li, F. X.; Shen, X. L.; Wang, J. Z. (2013). "Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: A randomised, double-blind, placebo-controlled phase 2 clinical trial".The Lancet.381 (9871):1037–1045.doi:10.1016/S0140-6736(12)61764-4.PMID23352749.S2CID27961719.
^De Thé, G.; Bomford, R.; Kazanji, M.; Ibrahim, F. (1994). "Human T Cell Lymphotropic Virus: Necessity for and Feasibility of a Vaccine".Ciba Foundation Symposium 187 - Vaccines Against Virally Induced Cancers. Novartis Foundation Symposia. Vol. 187. pp. 47–55, discussion 55–60.doi:10.1002/9780470514672.ch4.ISBN978-0-470-51467-2.PMID7796676.
^Rudoler, N.; Baneth, G.; Eyal, O.; Van Straten, M.; Harrus, S. (2012). "Evaluation of an attenuated strain of Ehrlichia canis as a vaccine for canine monocytic ehrlichiosis".Vaccine.31 (1):226–233.doi:10.1016/j.vaccine.2012.10.003.PMID23072894.
^Cullen, P. A.; Cameron, C. E. (2006). "Progress towards an effective syphilis vaccine: The past, present and future".Expert Review of Vaccines.5 (1):67–80.doi:10.1586/14760584.5.1.67.PMID16451109.S2CID31534855.
^Conlan, J. W. (2011). "Tularemia vaccines: Recent developments and remaining hurdles".Future Microbiology.6 (4):391–405.doi:10.2217/fmb.11.22.PMID21526941.
